Invasive fungal infections
Invasive fungal infections
Upon completion of the chapter, the reader will be able to: 1. Differentiate epidemiologic differences and host risk factors for acquisition of primary and opportunistic invasive fungal diseases. 2. Recommend appropriate empiric or targeted antifungal therapy for the treatment of invasive fungal disease. 3. Describe the components of a monitoring plan to assess effectiveness and adverse effects of pharmacotherapy for invasive fungal disease. 4. Evaluate the role of antifungal prophylaxis in the prevention of opportunistic fungal diseases.
Pharmacotherapy, antifungal, triazole, polynene, echinocandins, Invasive fungal infections, antifungals, polyenes, triazoles, echinocandins, invasive fungal disease, antifungal therapy, immunocompromised host, pharmacotherapy
Pharmacotherapy, antifungal, triazole, polynene, echinocandins, Invasive fungal infections, antifungals, polyenes, triazoles, echinocandins, invasive fungal disease, antifungal therapy, immunocompromised host, pharmacotherapy
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!